Invitae Aktie

Invitae EPS

Delisted·7. aug. 2024

Indtjening pr. aktie (EPS) for Invitae (NVTAQ) pr. 22. aug. 2026 er -5,23 USD. I foregående år var Indtjening pr. aktie (EPS) -12,73 USD — en ændring på -58,95 % (højere).

EPS

-5,23USD

YoY

-58,95%

Senest opdateret:

Indtjening pr. aktie (EPS) for Invitae er 2026 -5,23 USD. Indtjening pr. aktie (EPS) for Invitae var 2025 -12,73 USD. Det falder dermed med -58,95% højere sammenlignet med året før.
Access this data via the Eulerpool API

Invitae Aktieanalyse

Hvad laver Invitae? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Invitae aktie

Indtjening pr. aktie (EPS) for Invitae er -5,23 USD i 2026.

Indtjening pr. aktie (EPS) for Invitae ændrede sig fra -12,73 USD til -5,23 USD, hvilket repræsenterer en ændring på -58,95 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Indtjening pr. aktie (EPS) Invitae siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Indtjening pr. aktie måler den del af virksomhedens fortjeneste, der er allokeret til hver udestående aktie, og er en nøglekenntal til vurdering af en virksomheds rentabilitet pr. aktie.

EPS = Nettoindtjening / Udestående aktier

Access this data via the Eulerpool API

Resultatopgørelse — Invitae

Alle nøgletal — Invitae